Experience with extracorporeal elimination therapy in myasthenia gravis

被引：3

作者：

Blaha, Milan ^{[1
,2
]}

Pitha, Jiri ^{[3
,4
]}

Blaha, Vladimir ^{[2
,5
]}

Lanska, Miriam ^{[1
,2
]}

Maly, Jaroslav ^{[1
,2
]}

Filip, Stanislav ^{[2
,6
]}

Brndiar, Miroslav ^{[1
,2
]}

Langrova, Hana ^{[2
,7
]}

机构：

[1] Charles Univ Prague, Fac Med, Dept Internal Med 2, Hradec Kralove 50005, Czech Republic

[2] Teaching Hosp, Hradec Kralove 50005, Czech Republic

[3] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague 12000, Czech Republic

[4] Gen Teaching Hosp, Prague 12000, Czech Republic

[5] Charles Univ Prague, Fac Med, Dept Metab Care & Gerontol, Hradec Kralove 50005, Czech Republic

[6] Charles Univ Prague, Fac Med, Dept Radiotherapy & Oncol, Hradec Kralove 50005, Czech Republic

[7] Charles Univ Prague, Fac Med, Dept Ophthalmol, Hradec Kralove 50005, Czech Republic

来源：

TRANSFUSION AND APHERESIS SCIENCE | 2011年 / 45卷 / 03期

关键词：

Myasthenia gravis; Plasmapheresis; Immunotherapy; Myasthenic crisis; Extracorporeal elimination; PLASMA-EXCHANGE; INTRAVENOUS IMMUNOGLOBULIN; COMPLICATIONS; APHERESIS; PLASMAPHERESIS; DISEASE; CRISIS;

D O I：

10.1016/j.transci.2011.10.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We describe our experience with plasma exchange (PE) and immunoadsorption in patients with myasthenia gravis. The group of 27 patients consists of 21 patients treated with PE and 6 patients who received immunoadsorption. PE therapy led to stabilization in 20 patients. In patients treated with immunoadsorption, therapy could be discontinued in 2 patients after 13 months of therapy, and the other 4 patients were stabilized without myasthenic crises after 6-9 years of therapy. Extracorporeal elimination therapy through PE or immunoadsorption is effective and sometimes life saving and is safe in the hands of an experienced team (6% complication rate). (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：251 / 256

页数：6

共 26 条

[1] Complications of therapeutic plasma exchange: Experience with 4857 treatments [J].